We are providing an unedited version of this manuscript to give early access to its findings. Before final publication, the manuscript will undergo further editing. Please note there may be errors ...
The benefit from immune checkpoint blockade (ICB) can be mitigated by the onset of immune-related adverse events (irAEs). The identification of checkpoints specific to irAEs could mitigate toxicity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results